The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials.
The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.
Coleman
Robert L
RL
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rcoleman@mdanderson.org
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D005260:Female; D006176:Gynecology / Q000379:methods; D006801:Humans; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents